Bicycle Therapeutics has entered a 15-year contract with the UK Nuclear Decommissioning Authority for access to reprocessed uranium, which will support its therapeutic developments. Additionally, the company is collaborating with the UK National Nuclear Laboratory and SpectronRx to scale extraction and produce a bespoke 212Pb generator.
Company Information
Company
Bicycle Therapeutics
About
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development.
